Literature DB >> 32636098

DNA Repair and Prostate Cancer: A Field Ripe for Harvest.

Alan H Bryce1, Oliver Sartor2, Johann de Bono3.   

Abstract

Recent data have revealed antitumor activity for four PARP inhibitors, two of which (olaparib and rucaparib) are approved by the US Food and Drug Administration for metastatic castrate-resistant prostate cancer with selected DNA repair defects. Additional clinical trials are in progress for talazoparib, veliparib, and niraparib. More progress can be anticipated in the near future.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32636098     DOI： 10.1016/j.eururo.2020.06.020

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  6 in total

1.  The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.

Authors:  Gail P Risbridger; Ashlee K Clark; Laura H Porter; Mitchell G Lawrence; Renea A Taylor; Roxanne Toivanen; Andrew Bakshi; Natalie L Lister; David Pook; Carmel J Pezaro; Shahneen Sandhu; Shivakumar Keerthikumar; Rosalia Quezada Urban; Melissa Papargiris; Jenna Kraska; Heather B Madsen; Hong Wang; Michelle G Richards; Birunthi Niranjan; Samantha O'Dea; Linda Teng; William Wheelahan; Zhuoer Li; Nicholas Choo; John F Ouyang; Heather Thorne; Lisa Devereux; Rodney J Hicks; Shomik Sengupta; Laurence Harewood; Mahesh Iddawala; Arun A Azad; Jeremy Goad; Jeremy Grummet; John Kourambas; Edmond M Kwan; Daniel Moon; Declan G Murphy; John Pedersen; David Clouston; Sam Norden; Andrew Ryan; Luc Furic; David L Goode; Mark Frydenberg
Journal:  Nat Commun       Date:  2021-08-19       Impact factor: 14.919

2.  Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis.

Authors:  Tang Tang; Lin-Ang Wang; Peng Wang; Dali Tong; Gaolei Liu; Jun Zhang; Nan Dai; Yao Zhang; Gang Yuan; Kyla Geary; Dianzheng Zhang; Qiuli Liu; Jun Jiang
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

3.  Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes.

Authors:  Indu Kohaar; Xijun Zhang; Shiv Srivastava; Gyorgy Petrovics; Shyh-Han Tan; Darryl Nousome; Kevin Babcock; Lakshmi Ravindranath; Gauthaman Sukumar; Elisa Mcgrath-Martinez; John Rosenberger; Camille Alba; Amina Ali; Denise Young; Yongmei Chen; Jennifer Cullen; Inger L Rosner; Isabell A Sesterhenn; Albert Dobi; Gregory Chesnut; Clesson Turner; Clifton Dalgard; Matthew D Wilkerson; Harvey B Pollard
Journal:  Nat Commun       Date:  2022-03-15       Impact factor: 14.919

Review 4.  PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.

Authors:  Emily N Risdon; Cindy H Chau; Douglas K Price; Oliver Sartor; William D Figg
Journal:  Oncologist       Date:  2020-09-08       Impact factor: 5.837

Review 5.  Targeting DNA Damage Response in Prostate and Breast Cancer.

Authors:  Antje M Wengner; Arne Scholz; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923

6.  Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.

Authors:  Konrad H Stopsack
Journal:  Eur Urol       Date:  2020-10-01       Impact factor: 20.096
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.